328 related articles for article (PubMed ID: 25632203)
1. Vitamin D status and viral response to therapy in hepatitis C infected children.
Eltayeb AA; Abdou MA; Abdel-aal AM; Othman MH
World J Gastroenterol; 2015 Jan; 21(4):1284-91. PubMed ID: 25632203
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.
Nimer A; Mouch A
World J Gastroenterol; 2012 Feb; 18(8):800-5. PubMed ID: 22371640
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.
Abu-Mouch S; Fireman Z; Jarchovsky J; Zeina AR; Assy N
World J Gastroenterol; 2011 Dec; 17(47):5184-90. PubMed ID: 22215943
[TBL] [Abstract][Full Text] [Related]
5. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
6. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
[TBL] [Abstract][Full Text] [Related]
7. Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
Omori-Mizuno Y; Nakayama N; Inao M; Funyu J; Asabe S; Tomita K; Nishikawa K; Hosoda Y; Tanaka M; Hashimoto Y; Yakabi K; Koshima Y; Mochida S
J Gastroenterol Hepatol; 2015 Sep; 30(9):1384-90. PubMed ID: 25778685
[TBL] [Abstract][Full Text] [Related]
8. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
[TBL] [Abstract][Full Text] [Related]
9. Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy.
Espírito-Santo MP; Brandão-Mello CE; Marques VA; Lampe E; Almeida AJ
Ann Hepatol; 2013; 12(3):373-9. PubMed ID: 23619253
[TBL] [Abstract][Full Text] [Related]
10. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
[TBL] [Abstract][Full Text] [Related]
12. Association between vitamin D and hepatitis C virus infection: a meta-analysis.
Villar LM; Del Campo JA; Ranchal I; Lampe E; Romero-Gomez M
World J Gastroenterol; 2013 Sep; 19(35):5917-24. PubMed ID: 24124339
[TBL] [Abstract][Full Text] [Related]
13. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
[TBL] [Abstract][Full Text] [Related]
14. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
17. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
[TBL] [Abstract][Full Text] [Related]
18. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
19. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
